AN4005

AN4005, our clinically most advanced drug candidate from in-house discovery, is a potential first-in-class, orally available, small-molecule PD-L1 inhibitor.

 

We received IND clearance from the FDA for AN4005 for the treatment of advanced tumors in June 2021 and expect to identify recommended Phase II dose in the second half of 2022. AN4005 has exhibited excellent in vitro and in vivo activities, favorable safety profile, as well as the ability to promote adaptive immune response for antitumor efficacy in preclinical studies.

 

We believe that AN4005 has the potential to serve as a backbone drug in the emerging next wave of cocktail immuno-oncology therapies.


 Mechanism of Action
Clinical research

Advanced tumors

Clinical research
Latest progress
We received IND clearance from the FDA for AN4005 for the treatment of advanced tumors in June 2021.